Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021.

Corporate News FDA

Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALSOctober 18, 2021 5:26 AM Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual MeetingOctober 14, 2021 4:06 PM Biogen (BIIB) option implied volatility near low end of rangeOctober 13, 2021 10:43 AM Biogen (BIIB) Survey Data Conflicts with Bullish View, Piper Sandler Beginning to Get Concerned October 13, 2021 10:06 AM Biogen (BIIB) Expert Call Highlights Difficulties with Aduhelm Launch, Numbers Need to Come Down - JefferiesOctober 13, 2021 9:02 AM New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple SclerosisOctober 13, 2021 6:02 AM Biogen (BIIB) PT Lowered to $447 at Morgan StanleyOctober 12, 2021 2:41 AM